Lead Product(s) : STM2457
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STORM has identified novel, potent and selective first-in-class inhibitors of METTL3 that are orally bioavailable and show pronounced anti-tumour efficacy in animal models of AML, as well as solid tumours. This publication utilises STM2457, an earlier co...
Product Name : STM2457
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2021
Lead Product(s) : STM2457
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
